INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013	Mar. 31, 2012
CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]
Revenues	$ 194	$ 230	$ 584	$ 615
Cost of revenues	(6)	(6)	(18)	(18)
Gross profit	188	224	566	597
Research and development expenses	(4,965)	(3,421)	(12,859)	(9,253)
Less participation by the Office of the Chief Scientist and other parties	3	511	1,546	2,432
Research and development expenses, net	(4,962)	(2,910)	(11,313)	(6,821)
General and administrative expenses	(1,159)	(1,924)	(4,260)	(4,836)
Operating loss	(5,933)	(4,610)	(15,007)	(11,060)
Financial income, net	253	436	842	401
Net loss for the period	$ (5,680)	$ (4,174)	$ (14,165)	$ (10,659)
Loss per share:
Basic and diluted net loss per share	$ (0.10)	$ (0.09)	$ (0.26)	$ (0.24)
Weighted average number of shares used in computing basic and diluted net loss per share	58,358,476	44,328,201	54,507,538	43,585,104